New combo therapy aims to boost survival in tough esophageal cancers
NCT ID NCT05189730
First seen Nov 20, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This study looks at whether adding immunotherapy (tislelizumab) to chemotherapy can help high-risk patients with esophageal cancer who still have cancer after standard chemoradiation. About 80 participants will receive the combination, then surgery, and possibly more treatment based on results. The goal is to improve survival for high-risk patients while avoiding extra side effects for those at lower risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.